Princeton, Eli Lilly Sue Teva for Alleged Infringement of Chemotherapy Agent IP

Lilly and Princeton are suing a Teva US subsidiary for infringing on a US patent owned by Princeton and which serves as the basis for Alimta, Lilly’s chemotherapeutic compound for treating advanced lung cancer. The plaintiffs allege that Teva has infringed the patent by seeking approval to manufacture and sell a generic version of Alimta prior to the patent’s expiration.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.